Bladder Cancer
Research activity is centered on non-muscle invasive bladder cancer, with attention to patients whose disease remains unresponsive to BCG treatment.
- Immune checkpoint therapy
- Antibody-drug conjugates
- High-risk non-muscle invasive disease
The sponsor’s bladder cancer work reflects interest in treatment options for localized urothelial malignancy where preserving bladder function and controlling recurrence are key clinical concerns.
Colorectal Cancer
Another major area of focus is metastatic colorectal cancer, particularly in patients with later-line treatment needs and molecularly selected disease.
- EGFR-targeted therapy
- Chemotherapy rechallenge
- RAS wild-type
- BRAF wild-type
This research interest includes treatment strategies guided by liquid biopsy and biomarker-defined populations in advanced gastrointestinal cancer.
Biomarker-Driven Oncology
The sponsor is involved in trials that use molecular selection to identify patients most likely to benefit from treatment in advanced solid tumors.
- Liquid biopsy
- Genomic profiling
- Wild-type tumor selection
This area links translational oncology with targeted treatment selection in both bladder and colorectal cancer.
